Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Forum: Aktien User: Coronaprofiteur

Stark

Die Pharmaindustrie hatte es heute schwer. Es besteht die Befürchtung, dass auch auf Medikamente Einfuhrzölle erhoben werden. Sollte dies nicht geschehen, werden die Preise für Novo steigen.

Bin gerade in Holland und hier wird Novo im Netz als Favorit für die 2te Hälfte des Jahres angepriesen. Dann kann ja nix mehr schief gehen 😉

Oje

Nicht ganz aktuell, aber trotzdem neu hier?: Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out. By Elsa Ohlen June 13, 2025, 12:58 pm EDT The last time Novo Nordisk was Europe’s most valuable company was on March 24, 2025. (SERGEI GAPON/AFP via Getty Images) Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last month. Novo’s market capitalization is now $367 billion, pushing it above German software giant SAP’s $363 billion. The last time the Danish company held the top spot was in mid-March. On Friday, Novo stock was up as much as 2% in Denmark. Its American depositary receipts fell 0.8% to $80.39. Shares hit a low point in April, down nearly 60% in less than a year. Novo’s erosion over the past several months reflects the shift by investors to rival Eli Lilly. Several developments over the past weeks, however, are turning the tide—at least somewhat—back to Novo. The most recent development happened on Thursday, when Novo said it would fast-track its experimental weight-loss drug to late-stage clinical trials. Novo’s new drug, amycretin, combines the same GLP-1 hormone used in Ozempic and Wegovy with amylin, hormone that helps regulate appetite and blood sugar. Novo is developing both oral and subcutaneous versions. Novo’s yearlong struggle is to closely tied to a couple of big wins for Eli Lilly. Studies showed Lilly’s drug Zepbound promotes greater weight loss than Novo’s medicines. And Lilly’s new drug orforglipron has had promising results, while Novo’s next-generation weight-loss drug CagriSema hasn’t lived up to expectations. On Wednesday, Novo announced a new Phase 3 trial of CagriSema to try to assure investors of its potential. Lilly’s orforglipron is also a so-called small molecule drug, making it more scalable and easier to produce as a pill. Most drugs on the market now are injected. A weight-loss drug in pill form is especially important as the global market expands. A pill would be much easier to distribute because it doesn’t need to be shipped and refrigerated like an injectable. Novo employees have asserted the company isn’t aggressive enough in vying for market share and developing novel treatments, the healthcare news website STAT reported this month. When announcing the departure of CEO Lars Fruergaard Jørgensen, Novo leadership repeatedly emphasized that the company’s strategy remains the same. Still, moved by the company indicate a more forceful approach. This week, Novo signed a $812 million weight-loss drug license deal with U.S. biotech Deep Apple. In May, it announced a deal with San Francisco, Calif.-based Septerna to develop oral small-molecule weight-loss drugs. The Septerna deal is a risky move for a company that for a century has focused heavily on large molecules, or pharmaceuticals typically manufactured or extracted from living organisms. But if it works, Eli Lilly better watch out.

Was hat dich geritten?

hab eben mehr gekauft zu 58,80 € :S

Der Müll hat soviele aktien splits hingelegt das eine aktie nun 80 Stück sind.selbst Wenn der Kurs nochmal 20% fällt.ist das latte

Die Diskrepanz zwischen Zielanalysen und Kurs ist bei 40%. Hm. Skurril

https://fintel.io/ss/us/nvo Mittlerweile 7 Tagesumsätze als short Position. Haben die einem shortie die Freundin ausgespannt?

Meine Herren, sowas hast du doch nun oft genug gepostet. Es wird weder schlechte, noch besser, auch wenn du es noch x mal schreibst. Genau genommen ist nicht die Aktie Müll, sondern deine sinnfreien Beiträge!!!

so ein müll

Und hier nada nasser

Alle Märkte am ath

Nervt aber schon